Recruiting
A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer
NCT07741968· City of Hope Medical Center· Source
Contact: Anne Reb, MD
Recruiting
Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3
NCT07595874· Phase 2· City of Hope Medical Center· Source
Contact: Pashtoon M. Kasi
Recruiting
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
NCT07288034· Phase 2· City of Hope Medical Center· Source
Contact: Ravi Salgia
Recruiting
A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
NCT07225738· City of Hope Medical Center· Source
Contact: Richard T. Lee
Recruiting
Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
NCT07218510· Phase 2· City of Hope Medical Center· Source
Contact: Alexey V. Danilov
Recruiting
Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients
NCT07125729· City of Hope Medical Center· Source
Contact: Marwan G. Fakih
Recruiting
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
NCT06592924· Phase 3· Canadian Cancer Trials Group· Source
Contact: Tanya B. Dorff (principal investigator)
Active, not recruiting
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637· Phase 3· Pfizer· Source
Recruiting
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
NCT06337318· Phase 3· National Cancer Institute (NCI)· Source
Contact: Tycel J. Phillips (principal investigator)
Recruiting
Telehealth Self-Management Coaching Sessions to Improve Quality of Life in Pancreatic Cancer Survivors and Their Family Care Givers
NCT06524973· City of Hope Medical Center· Source
Contact: Vincent Chung, MD
Recruiting
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
NCT05890352· Phase 2· SWOG Cancer Research Network· Source
Contact: Alexey V. Danilov (principal investigator)
Recruiting
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
NCT05675410· Phase 3· National Cancer Institute (NCI)· Source
Contact: Alex F. Herrera (principal investigator)
Active, not recruiting
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
NCT05633602· Phase 3· SWOG Cancer Research Network· Source
Active, not recruiting
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
NCT05256225· Phase 3· National Cancer Institute (NCI)· Source
Recruiting
AOH1996 for the Treatment of Refractory Solid Tumors
NCT05227326· Phase 1· City of Hope Medical Center· Source
Contact: Vincent Chung, MD
Active, not recruiting
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
NCT04799275· Phase 2/3· National Cancer Institute (NCI)· Source
Recruiting
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
NCT04269902· Phase 3· National Cancer Institute (NCI)· Source
Contact: Alexey V. Danilov (principal investigator)
Active, not recruiting
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
NCT04579380· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source
Active, not recruiting
Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
NCT04508790· Phase 2· City of Hope Medical Center· Source
Recruiting
Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
NCT04305834· Phase 2· City of Hope Medical Center· Source
Contact: Thanh Nga Doan
Active, not recruiting
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
NCT03269669· Phase 2· National Cancer Institute (NCI)· Source